1.	Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus. Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 16-00017, NCT00754468
2.	Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0436, RTOG 0436, NCT00655876
3.	A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: 0806009855, NCT00760604
4.	An Open-Label, Single-Center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AT-101-CS-102, NCT00561197
5.	Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 82 Sponsor: Other Protocol IDs: Pro00002207, SPS 151596, NCT00578071
6.	Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 07326, NCT00667420
7.	Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-80302, NCT00316862
8.	Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-06013, NCT00354679
9.	Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 80 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: JHOC-J0386, J0386, JHOC-04-02-20-03, ZENECA-IRUSIRES0304, NCT00493025
10.	Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 65 Sponsor: NCI Protocol IDs: RPCI-I-62705, I 62705, NCT00524121
11.	Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001) Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: BrUOG-E-215, NCT00522795
12.	Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and GEJ Phase: Phase II Type: Treatment Status: Active Age: 75 and under Sponsor: Other Protocol IDs: 2003-0769, NCT00525785
13.	Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 2004-0703, NCT00525915
14.	Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: UMCC 2006.117, NCT00570531
15.	Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PR016-CLN-pro003, NCT00573131
16.	Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Locoregionally Advanced Cancer of the Esophagus, Gastroesophageal Junction, or Stomach Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: NCI Protocol IDs: CASE-2Y07, CASE2Y07, NCT00601705
17.	Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ACOSOG-Z4051, Z4051, NCT00757172
18.	Endoscopic Therapy of Early Cancer in Barretts Esophagus Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 1399-05, CA111603-01A1, NCT00217087
19.	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Esophagus Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: DMS-9939, NCI-G01-1931, NCT00014417
20.	A Study of V934/V935 in Cancer Patients With Selected Solid Tumors (Merck) Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2008_541, NCT00753415
21.	Randomized, Double Blind, Placebo-Controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NYU 05-409, NCT00821652
22.	Erlotinib Hydrochloride in Treating Patients With Previously Treated Non-Small Cell Lung Cancer, Head and Neck Cancer, or Esophageal Cancer and Precancerous Lesions of the Lung Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 40 to 79 Sponsor: NCI Protocol IDs: NU-NWU08-11-01, NWU08-11-01, NCI-08-11-01, RPCI-I-121507, NCT01013831
23.	Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life Phase: No phase specified Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 99-0522, NCT00260559
24.	Chemoradiation-Induced Nausea and Emesis: Quality of Life Phase: No phase specified Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2003-0529, NCT00394602
25.	Trial of Preoperative Capecitabine Oxaliplatin Cetuximab & Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NCT00060011, NCT00430027